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ABSTRACT
Introduction No predictive clinical or genetic markers 
have been identified or validated for antiangiogenic 
agents in lung cancer. We aimed to identify a predictive 
clinical marker of benefit for nintedanib, an angiokinase 
inhibitor, using data from two large second-line non-
small cell lung cancer Phase III trials (LUME-Lung 1 
([LL1] and LUME-Lung 2).
Methods Predictive marker identification was conducted 
in a multi-step process using data from both trials; a 
hypothesis was generated, confirmed and validated. 
Statistical analyses included a stepwise selection approach, 
a recursive partitioning method and the evaluation of 
HRs, including treatment-by-covariate interactions. The 
marker was finally validated using a prospectively defined 
hierarchical testing procedure and treatment-by-covariate 
interaction for overall survival (OS) based on LL1.
Results Time since start of first-line therapy (TSFLT) was 
identified as the only predictive clinical marker. A cut-off 
of 9 months was chosen for further analysis, based on 
HRs and recursive partitioning. The prospectively defined 
final validation using OS data from LL1 established the 
strong relationship between TSFLT and treatment with 
nintedanib. Patients with adenocarcinoma with TSFLT <9 
months showed a greater survival benefit (median OS 10.9 
vs 7.9 months, HR 0.75 [95% CI 0.60–0.92]; p=0.0073) 
compared with patients in the TSFLT >9 months group 
(median OS 17.0 vs 15.1 months, HR 0.89 [95% CI 
0.66–1.19]).
Conclusions Patients with shorter TSFLT derive a greater 
progression-free survival and OS benefit from nintedanib. 
This clinical marker could be used for patient selection 
and further investigation is warranted regarding pathways 
promoting aggressive tumour growth and antiangiogenic 
tyrosine kinase inhibitor benefit.
INTRODUCTION
The classification of advanced non-small 
cell lung cancer (NSCLC) includes the 
determination of histological and molec-
ular subtypes that influence therapeutic 
decisions.1 2 Histology is recognised as an 
important factor in treatment selection, as 
Key questions
What is already known about this subject?
 ► The classification of advanced non-small cell lung 
cancer (NSCLC) includes the determination of 
histological and molecular subtypes, which influence 
therapeutic decisions.
 ► No predictive clinical or molecular markers have 
been identified or validated for antiangiogenic 
agents in patients with advanced NSCLC.
What does this study add?
 ► This is the first study to identify a predictive clinical 
marker for antiangiogenic therapy in patients with 
advanced NSCLC.
 ► Predictive clinical markers of benefit for nintedanib, 
an angiokinase inhibitor, were evaluated using data 
from two large second-line NSCLC phase III trials 
(LUME-Lung 1 and LUME-Lung 2).
 ► A high threshold for success was set for developing 
the marker hypothesis, by requiring that any clinical 
marker should meet the criteria of being both 
prognostic of outcome in the control arms and 
predictive of treatment benefit in the investigational 
arms of the LUME-Lung trials. An additional threshold 
was that the observation made in one trial had to be 
validated in an independent trial in patients with the 
same histology.
 ► Time since start of first-line therapy (TSFLT) was 
shown to be the only prognostic and predictive 
clinical marker for treatment benefit with 
nintedanib.
How might this impact on clinical practice?
 ► TSFLT is the first independently validated clinical 
marker for antiangiogenic treatment in NSCLC, and 
is predictive and prognostic of treatment success 
with nintedanib.
 ► A shorter TSFLT is indicative that more aggressive 
tumours with a worse prognosis have a greater 
relative benefit from treatment with nintedanib.
 ► Further validation and characterisation of this 
clinical marker in future studies should help to 
define its potential utility in daily practice, as well as 
direct the search for a potential genetic marker to a 
narrower population.
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different histologies have distinct patterns of genomic 
alterations3 and differential responses to treatments.4 
Combination chemotherapies, including the vascular 
endothelial growth factor (VEGF) antibody bevacizumab, 
have shown different overall survival (OS) benefits based 
on histology.5 6 The lack of validated clinical or molec-
ular markers that can predict clinical benefit from VEGF 
receptor (VEGFR) inhibitors in patients with advanced 
NSCLC remains a significant unmet need. Identifying 
clinical markers that are predictive of antiangiogenic 
treatment effect would be particularly beneficial as it 
could help to guide future research into novel molecular 
markers, as well as potential pathways driving therapeutic 
resistance.
Nintedanib is an oral, triple angiokinase inhibitor 
of VEGFR1–3, platelet-derived growth factor receptor 
(PDGFR)-α/β, fibroblast growth factor receptor 
(FGFR)1–3, RET and Flt3.7 Nintedanib combined with 
docetaxel is approved in the European Union and 
other countries for the treatment of patients with locally 
advanced, metastatic or locally recurrent NSCLC of 
adenocarcinoma tumour histology after first-line chemo-
therapy, and has been approved as monotherapy for the 
treatment of patients with idiopathic pulmonary fibrosis. 
The LUME-Lung 1 study (NCT00805194; 1199.13) 
assessed nintedanib–docetaxel versus placebo–docetaxel 
in patients with advanced or recurrent NSCLC who had 
relapsed or failed one prior line of chemotherapy, and 
was the first phase III study to show a survival benefit of an 
add-on treatment versus an active comparator in a broad 
adenocarcinoma population.8 A separate study in patients 
with NSCLC showed similar findings; ramucirumab, a 
monoclonal antibody targeting the VEGFR2 receptor, 
significantly improved OS in patients with primarily 
non-squamous cell carcinoma when added to docetaxel.9 
Based on these promising data in molecularly unselected 
patients, there is a need to identify which patients may 
benefit most from antiangiogenic treatment.
Indeed, patient selection is particularly relevant with 
the increasing availability of different treatment options, 
such as immunotherapies, for patients progressing after 
first-line therapy. Although pembrolizumab is approved 
for patients with metastatic NSCLC after first-line therapy 
in a specific population of patients whose tumours 
express programmed death-ligand 1 (PD-L1), nivolumab 
is an available treatment option without a requirement 
for PD-L1 expression testing. However, PD-L1 expres-
sion levels do impact on outcome with nivolumab; the 
benefits of nivolumab over docetaxel were comparable 
regardless of PD-L1 expression status in squamous cell 
histology,10 whereas the magnitude of benefit appeared 
greater among patients whose tumours expressed PD-L1 
than among those whose tumours did not express PD-L1 
in patients with non-squamous histology NSCLC.11 
When combined with the observation that patients with 
non-squamous histology and low tumour PD-L1 expres-
sion (<50%) may be at higher risk of death within the 
first 3 months of treatment with nivolumab,12 PD-L1 
expression levels should be a consideration in the treat-
ment selection for both immunotherapy agents. Given 
that the majority of patients with NSCLC do not have 
high levels of PD-L1 expression,11 factors that can be used 
to guide treatment choice in these patients are particu-
larly welcome.
Against this background and concurrent with 
LUME-Lung 1, another phase III trial, LUME-Lung 2 
(NCT00806819; 1199.14), assessed nintedanib–peme-
trexed versus placebo–pemetrexed in patients with 
advanced or recurrent non-squamous NSCLC who had 
relapsed or failed one prior line of chemotherapy.13 Based 
on a preplanned futility analysis of investigator-assessed 
progression-free survival (PFS), the independent Data 
Monitoring Committee (DMC) recommended that this 
trial be stopped for futility because achievement of the 
primary endpoint was deemed to be unlikely.13 Follow-up 
was continued for previously accrued patients, and the 
DMC recommended exploring whether specific patients 
might benefit from nintedanib. Despite failing the futility 
analysis, subsequent analysis of centrally reviewed PFS, 
the primary study endpoint, demonstrated a statistically 
significant improvement in the nintedanib–pemetrexed 
arm (median, 4.4 vs 3.6 months, respectively; HR 0.83 
(95% CI 0.70–0.99); p=0.0435),13 indicating benefit 
from treatment with nintedanib–pemetrexed.
The objective of this analysis was to identify a predictive 
clinical marker of nintedanib benefit that could be used 
by clinicians to select patients most likely to benefit from 
the addition of nintedanib to docetaxel after first-line 
chemotherapy. Detailed analysis of the LUME-Lung 2 
data was conducted to identify a predictive and prognostic 
marker for nintedanib benefit, which was validated using 
data from the LUME-Lung 1 study. Identifying clinical 
markers that are predictive of antiangiogenic treatment 
effect would be particularly beneficial as it could help to 
guide future research into novel molecular markers, as 
well as potential pathways driving therapeutic resistance.
MATERIALS AND METHODS
Patients
LUME-Lung 1 and 2 were independent phase III trials 
in patients with stage IIIB/IV or recurrent NSCLC after 
failure of first-line chemotherapy, and Eastern Coopera-
tive Oncology Group (ECOG) performance status (PS) 
0–18 13 (figure 1). Only patients with relapse or failure 
of one previous first-line chemotherapy regimen were 
allowed to enter the study (in the case of recurrent 
disease one additional prior regimen was allowed for 
adjuvant, neo−adjuvant or neo−adjuvant plus adjuvant 
therapy). Both trials were approved by local indepen-
dent ethics committees or institutional review boards at 
each site, and by all relevant regulatory bodies.
LUME-Lung 1 assessed the efficacy and safety 
of nintedanib–docetaxel (n=655) versus placebo–
docetaxel (n=659) in all histological subtypes of NSCLC, 
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Figure 1 Overview of studies and clinical marker identification process. ECOG PS, Eastern Cooperative Oncology Group 
performance status; NSCLC, non-small cell lung cancer.
whereas LUME-Lung 2 assessed nintedanib–peme-
trexed (500 mg/m2; n=353) versus placebo–pemetrexed 
(n=360) in patients with non-squamous NSCLC.
In both trials, demographics and baseline characteris-
tics were balanced between treatment groups. Median age 
was ~60 years and just under one-third of patients were 
aged ≥65 years old. In LUME-Lung 1, 73% of patients 
were men, whereas this proportion was slightly lower in 
LUME-Lung 2 (57%). Median time since diagnosis in 
both trials was approximately 9 months and the large 
majority of patients (>97%) had received platinum-based 
first-line therapy. In LUME-Lung 1, 4% of patients had 
received first-line bevacizumab; this proportion was some-
what higher in LUME-Lung 2 (8%). Further details about 
the patient populations in these trials have been reported 
previously.8 13
In both trials, histology was a stratification factor 
(determined locally): squamous versus non-squamous 
in LUME-Lung 1 and adenocarcinoma versus non-ade-
nocarcinoma in LUME-Lung 2. Among the patients with 
non-squamous NSCLC, patients with adenocarcinoma 
represented the majority of the study population (87% in 
LUME-Lung 1% and 94% in LUME-Lung 2). The primary 
endpoint in both trials was PFS by central independent 
review according to modified Response Evaluation Criteria 
in Solid Tumours version 1.0. OS was the key secondary 
endpoint. In both trials, patient demographics and onco-
logical history were balanced between the treatment arms 
for the intention-to-treat populations and for the respective 
major histologies.
Clinical marker identification
Following the recommendation of the DMC, a systematic 
analysis of the LUME-Lung 2 trial was predefined and 
implemented to identify the patient population that gained 
most benefit from nintedanib treatment. For the clinical 
marker to be considered valid,14 15 and to reduce the likeli-
hood of falsely identifying a subgroup of patients benefiting 
from nintedanib, it was predefined that the marker was 
required to be both prognostic and predictive for PFS and 
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OS, and had to be confirmed with the independent set of 
LUME-Lung 1 data for PFS and OS.
By first identifying prognostic markers and testing only 
those for predictivity, the number of potential predictive 
variables was reduced and the chance of false-positive 
findings was decreased. A predefined range of patient 
baseline variables was explored to determine whether 
they were prognostic (table 1). These variables had been 
prespecified in the protocol or had been identified as 
potentially prognostic factors in the literature when the 
study was stopped because of futility.
Predictive marker identification was conducted in a 
four-step process, using data from both trials (figure 1). 
First, a hypothesis was generated by identifying prog-
nostic and predictive variables using data from the 
LUME-Lung 2 trial. Second, any prognostic and predic-
tive variables identified from hypothesis generation 
were confirmed using additional data from LUME-Lung 
2. Third, initial validation of the variable as predictive of 
nintedanib benefit was conducted using OS data from 
LUME-Lung 2 (internal validation) and data from the 
LUME-Lung 1 trial (external validation). As a final vali-
dation step, the prespecified key secondary endpoint of 
OS in the LUME-Lung 1 study was extended beyond the 
original specifications of the analysis plan to validate 
time since first-line therapy as a predictor of treatment 
benefit.
Because histology is recognised as an important factor 
in treatment selection for patients with advanced NSCLC, 
confirmation and validation of the marker was conducted 
in the non-squamous (LUME-Lung 2 only) and the 
adenocarcinoma patient populations; these represented 
the largest populations in both studies. This ensured the 
comparability of the results and reduced any population 
bias to a minimum.
STATISTICAL METHODS
Analysis of prognostic variables
Two different statistical methods were used to identify 
prognostic variables: (1) a stepwise selection approach 
using Cox proportional hazards modelling and (2) a 
recursive partitioning tree approach (see online supple-
mentary appendix for further details).16
Cox proportional hazards modelling included all 
prespecified baseline variables in a stepwise selection 
model. The two major stratification factors (based on 
patient numbers) used in the LUME-Lung trials (ECOG 
PS [0 vs 1] and tumour histology [adenocarcinoma vs 
non-adenocarcinoma]) were included in the model as 
stratification factors. The critical value for inclusion or 
exclusion of a potentially prognostic variable was the 
significance level of 0.05.
Prognostic analyses were conducted using PFS data 
from the control arm of the LUME-Lung 2 study. Investi-
gator-assessed PFS was used during hypothesis generation 
and centrally assessed PFS data were used during confir-
mation.
Table 1 Investigated prognostic variables
Baseline characteristic
Randomisation 
stratification 
factor
Prespecified 
in both 
protocols
Tumour histology (LUME-
Lung 1: squamous vs 
non-squamous; LUME-
Lung 2: adenocarcinoma 
vs non-adenocarcinoma)
 ✓
Baseline ECOG 
performance status (0 
vs 1)
 
Prior bevacizumab 
therapy (yes vs no)
 
Brain metastases at 
baseline (yes vs no)
 
Liver metastases (yes vs 
no)
 
Sex (men vs women)  
Age (<65 vs ≥65 years)  
Best response to first-line 
chemotherapy (CR/PR/
SD vs PD/unknown/NA/
missing)
 
Concomitant 
bisphosphonates at 
baseline (yes vs no)
 
Disease stage at 
diagnosis (<IIB/IV vs IIIB 
vs IV)
 
Region (LUME-Lung 1: 
Asia vs rest of world; 
LUME-Lung 2: Asia vs 
non-Asia)
 
Time between start of 
first-line therapy and 
randomisation into the 
trial (‘TSFLT’) (months)
 
Adrenal metastases (yes 
vs no)*
 
Number of metastatic 
organs at baseline*
 
Lactate dehydrogenase 
level at baseline* (>1 x 
ULN vs≤1 x ULN)†
 
*Additionally identified from the literature.
†Lactate dehydrogenase (LDH) levels at baseline were transformed 
into a binary variable (>1 ×  ULN vs ≤1 ×  ULN) because the range of 
LDH values was very limited (5th percentile, 0.5; 95th percentile, 2.0). 
This categorisation of LDH levels has been used previously.47,48
✓=yes; ✗=no; CR, complete response; ECOG, Eastern Cooperative 
Oncology Group; NA, not available; PD, progressive disease; PR, 
partial response; SD, stable disease; TSFLT, time since start of first-
line therapy; ULN, upper limit of normal.
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Analysis of predictive variables
To investigate whether prognostic variables were also 
predictive for the treatment effect, the interaction 
between these variables and treatment was examined by 
a stepwise selection approach using Cox proportional 
hazards modelling with data from LUME-Lung 2.
For the calculation of HRs and 95% CIs, the Cox 
proportional hazards model was stratified by the LUME-
Lung 2 stratification factors: ECOG PS (0 vs 1), tumour 
histology (adenocarcinoma vs non-adenocarcinoma), 
brain metastases at baseline (yes vs no) and prior treat-
ment with bevacizumab (yes vs no). Investigator-assessed 
PFS was used during hypothesis generation and centrally 
assessed PFS data were used during confirmation. Formal 
interaction tests were used for categorical covariates; 
treatment-by-covariate interaction was evaluated at a 
significance level of 0.2.
Hazard ratio-by-treatment interaction plots
Assessment of treatment interaction for continuous vari-
ables was evaluated by calculating HRs for various covariate 
levels, which were depicted visually by HR-by-treatment 
interaction plots.17 18 No formal interaction tests were 
performed; the covariate values below which the HR point 
estimate was <1 and for which the width of the 95% CI was 
small were considered to define a subgroup of patients 
with greater treatment benefit.
HR-by-treatment interaction plots were used throughout 
the analyses and in the validation of the interaction 
between treatment effect and continuous variables, using 
the OS data from LUME-Lung 2 (internal validation) and 
OS data from LUME-Lung 1 (external validation).
FINAL VALIDATION
The final analysis of the key secondary endpoint OS of the 
LUME-Lung 1 trial was planned to be extended to validate 
this potential clinical marker by prospectively introducing 
hierarchical testing as follows8 : (1) patients as defined 
by the predictive marker within the identified tumour 
histology groups (non-squamous or adenocarcinoma), 
(2) patients with the identified tumour histology groups 
(non-squamous or adenocarcinoma) and (3) the entire 
study population. In order to define clearly the beneficial 
group of patients for the first step of this testing proce-
dure, any predictive continuous marker would require 
dichotomisation by an appropriate cut-point. With this 
hierarchy, each of the three hypotheses could be tested 
at the prespecified significance level only if the previous 
null hypothesis in the testing sequence had been rejected 
(and after a statistically significant result for the primary 
endpoint PFS in the primary and follow-up PFS analyses 
for LUME-Lung 1 had been achieved). The overall alpha 
level for OS followed a Lan–DeMets spending function 
with an O’Brien–Fleming shape parameter19 to preserve 
an overall two-sided alpha level of 0.05. The significance 
level for each step of this final OS analysis was 0.04984, 
and depended on the number of deaths that had accrued 
at the time of the interim OS analysis (n=423 OS events) 
and the number of deaths that had accrued by the time of 
the final OS analysis (n=1121 OS events).
In order to validate the predictivity of the clinical 
marker, the treatment interaction should be confirmed 
— for binary variables, by repeating the interaction test; 
and for continuous variables, by evaluating the HR–inter-
action plot. In addition, the estimated OS treatment 
benefit from the first hierarchical testing step should be 
greater compared with the OS treatment benefit of the 
second testing step and of the last testing step.
RESULTS
Hypothesis generation based on LUME-Lung 2
Stepwise selection analyses of the placebo arm of the 
LUME-Lung 2 study identified TSFLT (defined as time 
between start of first-line therapy and randomisation into 
the trial; HR 0.96 [95% CI 0.94–0.98; p=0.0001]), male sex 
(HR 1.33 [95% CI 0.94–1.87; p=0.1045]), lower baseline 
lactate dehydrogenase (LDH) levels (HR 1.34 [95% CI 
1.07–1.66; p=0.009]) and having never smoked (HR 1.59 
[95% CI 1.10–2.30; p=0.0135]) as potentially prognostic for 
longer PFS.
Recursive partitioning also identified TSFLT as poten-
tially prognostic, with an optimal binary split for TSFLT of 
7.8 months (see online  supplementary figure 1A).
The HR-by-treatment interaction plot of TSFLT based 
on investigator-assessed PFS showed that patient benefit 
from nintedanib treatment was higher with shorter 
TSFLT. The upper limit of the 95% CI approached a HR 
of 1.0 at TSFLT values between 8 and 9 months. A cut-off 
of 9 months (ie, TSFLT <9 months vs TSFLT ≥9 months) 
was chosen for further exploratory analysis, as the 95% 
CIs were narrowest around this point and similar to the 
cut-off identified by recursive partitioning.
Further analysis revealed that TSFLT was the only 
predictive marker for the treatment effect of nintedanib 
in combination with pemetrexed. The HR for patients 
with TSFLT <9 months was 0.76 (95% CI 0.58–0.98). 
Owing to the high frequency of patients with adeno-
carcinoma in the LUME-Lung 2 study, this finding 
was mainly driven by these patients (HR 0.96 [95% CI 
0.78–1.17], nintedanib–pemetrexed vs placebo–peme-
trexed).
Confirmation of the predictive marker
Stepwise selection analysis of centrally assessed PFS in the 
LUME-Lung 2 placebo arm identified TSFLT (HR 0.95 
[95% CI 0.93–0.98; p<0.0001]), baseline LDH levels (HR 
1.52 [95% CI 1.23–1.89; p=0.0001]), region (Asian vs 
non-Asian) (HR 1.53 ([95% CI 1.12–2.10; p=0.0073]) and 
presence/absence of liver metastases (HR 1.42 [95% CI 
0.97–2.08; p=0.0676]) as potentially prognostic variables. 
Recursive partitioning analysis of centrally assessed PFS 
in the LUME-Lung 2 placebo arm confirmed TSFLT as a 
prognostic variable, with an optimal binary split point of 
8.2 months (see online supplementary figure 1B).
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Further analysis showed that TSFLT was also the only 
predictive variable of nintedanib benefit; the p values of 
the treatment-by-covariate interaction tests for other vari-
ables were all above 0.2 (figure 2).
The HR–treatment interaction plot confirmed the rela-
tionship between HR and TSFLT, with the upper limit 
of the 95% CI approaching a HR of 1.0 at TSFLT values 
between 8 and 9 months. This finding was confirmed 
in analysis of patients with adenocarcinoma tumour 
histology (figure 3A), and Kaplan–Meier curves demon-
strated a significant treatment benefit (figure 4A).
Initial validation of the predictive marker
The interaction between treatment effect and TSFLT 
was validated using the OS data from LUME-Lung 2: the 
shorter the TSFLT, the better the treatment effect, as indi-
cated by a decreasing HR with shorter TSFLT in patients 
with either non-squamous or adenocarcinoma histology 
tumours. In both patients with non-squamous histology 
with TSFLT <9 months and patients with adenocarcinoma 
histology with TSFLT <9 months, the HR for OS was 0.84 
(95% CI 0.62–1.14).
The HR-by-treatment interaction plots based on 
centrally assessed PFS and the interim OS for the patients 
with non-squamous cell carcinoma in LUME-Lung 1 vali-
dated the relationship between TSFLT and HR observed 
in the LUME-Lung 2 data. The same relationship between 
TSFLT and HR was observed in patients with adenocar-
cinoma for centrally assessed PFS (figure 3B) and the 
interim OS.
For patients with adenocarcinoma histology and 
TSFLT <9 months, the HR for centrally assessed PFS 
was 0.63 (95% CI 0.48–0.83) (figure 4B) and the HR for 
interim OS was 0.79 (95% CI 0.55–1.14). PFS benefit 
was also observed in patients with TSFLT <6 months 
(see online supplementary figure 2A). Of note, in the 
patients with squamous cell carcinoma, no relationship 
between this marker and either PFS or OS treatment 
effects was observed.
Final validation
The first testing step for the final OS data from LUME-
Lung 1 established that patients with adenocarcinoma 
with TSFLT <9 months showed a greater survival 
benefit. In these patients, nintedanib–docetaxel signifi-
cantly prolonged median OS by 3 months compared 
with placebo–docetaxel, and reduced the risk of death 
by 25% (figure 4C) (median final OS 10.9 months 
[95% CI 8.5–12.6] vs 7.9 months [95% CI 6.7–9.1], HR 
0.75 [95% CI 0.60–0.92]; p=0.0073). In the group with 
TSFLT ≥9 months, the HR for OS was 0.89 (95% CI 0.66–
1.19; p=0.4239, median OS 17.0 vs 15.1 months).
The assessment of OS HRs for various levels of TSFLT in 
the LUME-Lung 1 study shows that patients with adeno-
carcinoma with the shortest TSFLT derived significant 
treatment benefit for OS when treated with nintedanib–
docetaxel (figure 3C). More importantly, however, this 
confirmed that the overall population of patients with 
adenocarcinoma derived a treatment benefit, as the esti-
mated HR stayed below 1, irrespective of the TSFLT. Of 
note, the upper limit of the 95% CI did cross 1 at around 
the time of 12 months since start of first-line therapy.
In line with the predictive effect of TSFLT, patients 
with TSFLT <6 months (median final OS 9.5 months 
Figure 2 Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-
small cell lung cancer with non-squamous histology treated in LUME-Lung 2. Treatment-by-covariate interaction tests for HRs 
using data from patients treated with nintedanib–pemetrexed. LDH, lactate dehydrogenase. aHRs and CIs obtained from a 
model stratified by Eastern Cooperative Oncology Group performance status (0 vs ≥1), brain metastases at baseline (yes vs 
no), prior treatment with bevacizumab (yes vs no) and tumour histology (adenocarcinoma vs non-adenocarcinoma).
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[95% CI 6.4–12.0] vs 7.5 months [95% CI 5.9–8.6], HR 
0.73 [95% CI 0.55–0.98]; p=0.0327) (see online supple-
mentary figure 2B) and patients who had only progressive 
disease as best response during first-line treatment 
(median OS 9.8 months [95% CI 6.1–15.5] vs 6.3 months 
[95% CI 5.0–8.1], HR 0.62 [95% CI 0.41–0.94]) showed 
a greater survival benefit (see online supplementary 
figure 2C).
Additional evaluation of the data showed that TSFLT was 
strongly correlated with time to disease progression on first-
line therapy in both studies (Pearson correlation coefficient 
for the nintedanib arm: 0.93 for LUME-Lung 2 [follow-up 
data] and 0.97 for LUME-Lung 1 [final OS data]).
Discussion
Using data from two large, independent trials, we have 
identified and independently confirmed TSFLT as a 
prognostic and predictive clinical marker of nintedanib 
benefit in patients with pretreated advanced NSCLC 
of adenocarcinoma histology receiving concomitant 
chemotherapy with docetaxel or pemetrexed. A rigorous 
methodology was used to ensure the validity of TSFLT 
as a clinical marker. This clinical marker specifically 
defined a population of patients with adenocarcinoma 
histology and TSFLT <9 months; this population experi-
enced a 3-month improvement in median OS and more 
than double the median PFS compared with placebo–
docetaxel in LUME-Lung 1. Confirmation of the cut-off 
point for TSFLT of 9 months was also validated using 
an additional methodology (see online supplementary 
appendix). Taken together with the OS benefits reported 
in the LUME-Lung 1 study for the overall adenocarcinoma 
population, these findings suggest that early progressors 
with adenocarcinoma histology may benefit relatively 
more from nintedanib-based combination treatment. 
To our knowledge, this is the first report of a predictive 
clinical marker of benefit for an antiangiogenic tyrosine 
kinase inhibitor in patients with NSCLC, which has been 
validated in an independent trial. TSFLT represents an 
easy-to-assess parameter and, given that shorter time is 
associated with more aggressive tumour characteristics, 
TSFLT represents a clinically relevant factor that can be 
used to guide treatment choice.
Results from the REVEL study also confirm TSFLT as 
a potential clinical marker for the efficacy of antiangio-
genic therapy in patients with advanced NSCLC; TSFLT 
was one of the most predictive factors for ramucirumab 
in the second-line NSCLC setting.9 Interestingly, the 
Figure 3 HR by treatment interaction plots for time since start of first-line therapy in patients with advanced adenocarcinoma 
histology. (A) Centrally assessed PFS (primary analysis) in patients treated with nintedanib–pemetrexed in LUME-Lung 2, (B) 
centrally assessed PFS (primary analysis) and (C) final OS in patients treated with nintedanib–docetaxel in LUME-Lung 1. OS, 
overall survival; PFS, progression-free survival.
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opposite is true for the anti-PD-L1 inhibitor nivolumab; 
OS benefit with nivolumab treatment was greatest in 
patients with non-squamous NSCLC with >6 months 
since completion of their most recent platinum-based 
doublet chemotherapy regimen.11 Additional post–hoc 
analyses have shown that nivolumab-treated patients 
with poorer prognostic features and/or aggressive 
disease, when combined with low tumour PD-L1 expres-
sion (<50%), may be at higher risk of death within the 
first 3 months of treatment.12 As such, TSFLT may be a 
useful factor to guide second-line treatment selection.
Time to progression or time since completion of therapy 
has been used in other trials to characterise early-pro-
gressing or refractory NSCLC patient populations using 
similar time frames to the 9-month cut-off identified 
here.20–23 From a clinical perspective, a cut-off of 9 months 
since start of first-line therapy to define early progressors 
is also logical, given the average duration of first-line plat-
inum-containing chemotherapy (~4.5–5 months) and the 
timing of routine CT scanning after the end of the first-
line regimen (6–8-week intervals). Furthermore, time to 
progression is an established clinical marker in ovarian 
cancer.24
We hypothesise that there is a scientific rationale to 
explain the benefit of nintedanib-based treatment that is 
observed in adenocarcinoma early progressors, which is 
related to the biology of rapidly progressing tumours as 
well as the unique biology of adenocarcinoma. Rapidly 
progressing tumours contain a large proportion of 
proliferating cells and require high levels of oxygen 
and nutrients. As such, the growth of these tumours 
may particularly depend on the development of new 
blood vessels, which may render them more sensitive 
to the effects of antiangiogenic treatment than slowly 
progressing tumours. This hypothesis is supported by 
an analysis of gene expression. Clinical outcome data 
derived from a large NSCLC database were analysed using 
a gene set enrichment analysis that was applied to robust 
multi-array average normalised expression data gener-
ated by the Director’s Challenge Consortium.25 That 
analysis showed that genes relevant to cell proliferation 
are more frequently expressed in lung adenocarcinomas 
Figure 4 Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma 
histology with time since start of first-line therapy <9 months. (A) Centrally assessed PFS (primary analysis) in patients treated 
in LUME-Lung 2, (B) centrally assessed PFS (primary analysis) and (C) final OS in patients treated in LUME-Lung 1. OS, overall 
survival; PFS, progression-free survival.
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from patients with early disease progression, indicating 
a large fraction of proliferating cells.26 The potential 
ability of nintedanib to provide sustained blockade of the 
major angiokinases involved in tumour vascularisation 
(VEGFR-1–3, PDGFR-α/α and FGFR-1–37) may enhance 
the effectiveness of combination treatment and help to 
overcome the compensatory angiogenic signalling that 
has been observed when anti-VEGF/VEGFR agents are 
used alone.27 We cannot exclude other possible reasons 
for the benefit of nintedanib-based treatment in adeno-
carcinoma early progressors, and further study would be 
needed to do so. However, we have observed no other 
obvious clinical features of these patients that could 
contribute to the effect seen.
As shown here, histological subtype has been linked to 
the therapeutic outcome of patients with NSCLC in other 
studies, including the E4599 study with bevacizumab,6 
the REVEL study with ramucirumab9 and meta-anal-
yses;28 29 all have shown an OS benefit with antiangiogenic 
compounds in combination with a taxane in patients 
with non-squamous/adenocarcinoma NSCLC. Potential 
differences in treatment effect in different histologies 
may relate to the molecular profile of adenocarcinoma, 
which is largely different from squamous cell cancer 
histology.30–34
There have been extensive research efforts to identify 
predictive markers of benefit from antiangiogenic therapy 
in NSCLC. Hypertension has been suggested as a predic-
tive marker for efficacy, but has not been validated and 
recent meta-analyses showed no association.35 In our anal-
ysis, LDH levels were identified as a prognostic marker, 
as observed previously in several cancers,36 including 
NSCLC.37 However, LDH levels were not predictive for the 
effect of nintedanib here, as has been reported with some 
antiangiogenic agents in metastatic colorectal cancer.38–40
Other studies have also shown a link between markers 
associated with more aggressive tumours/worse prognosis 
and greater relative benefit from antiangiogenic treat-
ment.41–43 High baseline VEGF levels are associated with 
worse prognosis, and they are predictive of benefit from 
treatment with bevacizumab in patients with NSCLC42 
or gastric cancer,41 although they were not predictive in 
other studies.44 Similarly, high baseline levels of inter-
leukin-6 predicted poor prognosis in patients with renal 
cell carcinoma, but greater relative benefit from the 
antiangiogenic pazopanib.43 The antiangiogenic agent 
vandetanib combined with docetaxel has been shown to 
have a higher activity in pretreated NSCLC with a high 
epidermal growth factor receptor (EGFR) gene copy 
number or activating EGFR mutations than docetaxel 
alone; however, this effect is most likely linked to its dual 
EGFR inhibitory effect.45 Low baseline circulating VEGF 
levels were also identified in an exploratory analysis as a 
predictive marker for vandetanib efficacy.46
The LUME-Lung trials were largely comparable in 
patient characteristics and study design8 13 and the 
reported efficacy data in the control arms were compa-
rable with those reported previously for second-line 
therapies. Thus, both studies were considered to be 
adequate for justifying the identification and valida-
tion of the clinical marker. Limitations of this analysis 
include the fact that assessment of predictive clinical 
markers was not a primary or key secondary endpoint 
in these studies, and the early termination of the LUME-
Lung 2 study.
In conclusion, TSFLT was shown to be the only prognostic 
and predictive clinical marker for the treatment effect of 
nintedanib combined with either docetaxel or pemetrexed 
in patients with advanced NSCLC of adenocarcinoma 
histology progressing following chemotherapy. This clinical 
marker defined that patients with shorter TSFLT who have 
a poorer prognosis derive a greater PFS and OS benefit 
from nintedanib. This marker could be used for patient 
selection, and further investigation is warranted regarding 
pathways promoting aggressive tumour growth and angio-
genic tyrosine kinase inhibitor benefit.
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